About US
Contact us
-
Adapt's new bargain-priced OD antidote enters contentious marketThe rising number of opioid-related deaths in the U.S. has translated into big opportunity for pharmas selling the antidote med naloxone, with drugmakers such as Amphastar Pharmaceuticals ($AMPH) gett2015/11/20
-
Pfizer prepared to risk a 3% breakup fee for chance at Allergan, sources tell ReutersBreaking up can be hard to do. It can also be expensive, which would be the case for Pfizer if the roughly $150 billion deal it is reportedly negotiating with Allergan were to go south. But the potent2015/11/20
-
Big three PBMs cut loose more specialty pharmacies as scrutiny growsPharmacy benefit managershave broadened their crackdown on specialty pharmacies, with at least 8 cut off from reimbursement in recent days. The PBMs are targeting pharmacies with close ties to particu2015/11/17
-
History suggests a Pfizer-Allergan hookup would mean sizable cuts in manufacturingToday Pfizer ($PFE) has about 65 plants since picking upHospirain September. A hookup with Allergan ($AGN), which the two have acknowledged they are exploring, would add another 40. That inevitably le2015/11/17
-
Merck may appeal to Supreme Court after again losing fight to protect Cubicin patentsMerck & Co. ($MRK) is running low on options after a federal appeals court Thursday again declined to back four patents that would have held at bay for 5 more years generics of the antibioticCubic2015/11/16
-
Mylan fails in hostile quest to buy PerrigoPharma's longest-running takeover battle of the year has come to an end--and not in pursuer Mylan's ($MYL) favor. The company has failed to garner the support necessary for a takeover of Perrigo ($PR2015/11/16
-
AstraZeneca hikes full-year forecast as Nexium holds its own, Brilinta deliversAstraZeneca ($AZN) has so far weathered theNexiumpatent cliff well enough to actually raise its full-year sales forecast for 2015. ItsBrilintagrowth strategy appears to be paying off. But the U.K.-bas2015/11/6
-
U.K. cancer fund strikes discount deal with Roche to keep Kadcyla coveredLast month, the U.K.'s special Cancer Drugs Fund gave the boot to a slate of therapies, including Roche's ($RHHBY) treatmentKadcyla--a decision the Swiss drugmaker's CEO called "stupid" and "completel2015/11/6
-
Everybody's talking about the Pfizer-Allergan courtship. Here's the juiciest chat we overheardThe deal of the year could be arranged by Thanksgiving, or so goes the story. Despite opposition from politicians, despite the tricky nature of pulling off a tax inversion that size, Pfizer ($PFE) and2015/11/3
-
FDA cites Pfizer for shortfalls at Chinese manufacturing plantTheFDAand European regulators, which have long had concerns about the quality of drugs being manufactured by Chinese companies, are now finding issues at some Chinese plants owned by Big Pharma. The F2015/11/3